Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in The Netherlands Before and After Transition to Adult Care.

Weijsenfeld AM, Smit C, Cohen S, Wit FW, Mutschelknauss M, van der Knaap LC, van Zonneveld LM, Zomer BJ, Nauta N, Patist JC, Kuipers-Jansen MH, Smit EP, Blokhuis C, Pajkrt D; Dutch HIV Adolescents and Young Adults (AYA) Study Group..

Clin Infect Dis. 2016 Oct 15;63(8):1105-12. doi: 10.1093/cid/ciw487.

PMID:
27439528
2.

Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.

Rokx C, Gras L, van de Vijver D, Verbon A, Rijnders B; ATHENA National Observational Cohort Study..

HIV Med. 2016 Sep;17(8):571-80. doi: 10.1111/hiv.12355.

PMID:
26842457
3.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

Mocroft A, Lundgren JD, Ross M, Fux CA, Reiss P, Moranne O, Morlat P, Monforte Ad, Kirk O, Ryom L; Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study..

Lancet HIV. 2016 Jan;3(1):e23-32. doi: 10.1016/S2352-3018(15)00211-8.

PMID:
26762990
4.

Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996-2014: results from a national observational cohort.

Op de Coul EL, van Sighem A, Brinkman K, van Benthem BH, van der Ende ME, Geerlings S, Reiss P; ATHENA National Observational HIV Cohort..

BMJ Open. 2016 Jan 4;6(1):e009688. doi: 10.1136/bmjopen-2015-009688.

5.

Acute hepatitis C in the Netherlands: characteristics of the epidemic in 2014.

Hullegie SJ, van den Berk GE, Leyten EM, Arends JE, Lauw FN, van der Meer JT, Posthouwer D, van Eeden A, Koopmans PP, Richter C, van Kasteren ME, Kroon FP, Bierman WF, Groeneveld PH, Lettinga KD, Soetekouw R, Peters EJ, Verhagen DW, van Sighem AI, Claassen MA, Rijnders BJ.

Clin Microbiol Infect. 2016 Feb;22(2):209.e1-3. doi: 10.1016/j.cmi.2015.10.012.

6.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration..

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3.

7.

Chronic Q Fever Diagnosis— Consensus Guideline versus Expert Opinion.

Kampschreur LM, Wegdam-Blans MC, Wever PC, Renders NH, Delsing CE, Sprong T, van Kasteren ME, Bijlmer H, Notermans D, Oosterheert JJ, Stals FS, Nabuurs-Franssen MH, Bleeker-Rovers CP; Dutch Q Fever Consensus Group..

Emerg Infect Dis. 2015 Jul;21(7):1183-8.

8.

Cutaneous hyperpigmentation induced by doxycycline: a case series.

Keijmel SP, van Kasteren ME, Blokx WA, van der Meer JW, van Rossum M, Bleeker-Rovers CP.

Neth J Med. 2015 Jan;73(1):37-40.

9.

Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.

Bruyand M, Ryom L, Shepherd L, Fatkenheuer G, Grulich A, Reiss P, de Wit S, D Arminio Monforte A, Furrer H, Pradier C, Lundgren J, Sabin C; D:A:D study group..

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77. doi: 10.1097/QAI.0000000000000523.

PMID:
25763785
10.

Diminished impact of ethnicity as a risk factor for chronic kidney disease in the current HIV treatment era.

Schoffelen AF, Smit C, van Lelyveld SF, Vogt L, Bauer MP, Reiss P, Hoepelman AI, Barth RE; ATHENA National Observational HIV Cohort..

J Infect Dis. 2015 Jul 15;212(2):264-74. doi: 10.1093/infdis/jiv026.

PMID:
25601941
11.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration., Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167.

12.

Changes in HIV RNA and CD4 cell count after acute HCV infection in chronically HIV-infected individuals.

Gras L, de Wolf F, Smit C, Prins M, van der Meer JT, Vanhommerig JW, Zwinderman AH, Schinkel J, Geskus RB; ATHENA national observational cohort and the MOSAIC study..

J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):536-42. doi: 10.1097/QAI.0000000000000514.

PMID:
25559595
13.

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.

Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska JD, de Wit S, Law M, el Sadr W, Kirk O, Friis-Moller N, Monforte Ad, Phillips AN, Sabin CA, Lundgren JD; D:A:D Study Group..

Lancet. 2014 Jul 19;384(9939):241-8. doi: 10.1016/S0140-6736(14)60604-8.

PMID:
25042234
14.

Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study.

Kamara DA, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux CA, Mocroft A, Sabin C, Lundgren JD, Smith CJ; D:A:D study Group..

BMC Nephrol. 2014 Mar 25;15:51. doi: 10.1186/1471-2369-15-51.

15.

Chronic Q fever in the Netherlands 5 years after the start of the Q fever epidemic: results from the Dutch chronic Q fever database.

Kampschreur LM, Delsing CE, Groenwold RH, Wegdam-Blans MC, Bleeker-Rovers CP, de Jager-Leclercq MG, Hoepelman AI, van Kasteren ME, Buijs J, Renders NH, Nabuurs-Franssen MH, Oosterheert JJ, Wever PC.

J Clin Microbiol. 2014 May;52(5):1637-43. doi: 10.1128/JCM.03221-13.

16.

[Neonatal outcomes of prevention of vertical HIV transmission; 15 years of experience in a non-university HIV centre].

Veen CA, van Kasteren ME, Fiedeldeij CA, Kuipers MH, van Dijken PJ, Obihara CC.

Ned Tijdschr Geneeskd. 2014;158(6):A6508. Dutch.

PMID:
24495366
17.

A combination of interferon-gamma and interleukin-2 production by Coxiella burnetii-stimulated circulating cells discriminates between chronic Q fever and past Q fever.

Schoffelen T, Sprong T, Bleeker-Rovers CP, Wegdam-Blans MC, Ammerdorffer A, Pronk MJ, Soethoudt YE, van Kasteren ME, Herremans T, Bijlmer HA, Netea MG, van der Meer JW, Joosten LA, van Deuren M.

Clin Microbiol Infect. 2014 Jul;20(7):642-50. doi: 10.1111/1469-0691.12423.

18.

Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study.

Worm SW, Bower M, Reiss P, Bonnet F, Law M, Fätkenheuer G, d'Arminio Monforte A, Abrams DI, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren JD, Sabin CA; D:A:D Study Group..

BMC Infect Dis. 2013 Oct 9;13:471. doi: 10.1186/1471-2334-13-471.

19.

Changes in first-line cART regimens and short-term clinical outcome between 1996 and 2010 in The Netherlands.

Smit M, Smit C, Geerlings S, Gras L, Brinkman K, Hallett TB, de Wolf F; Athena Observational Cohort..

PLoS One. 2013 Sep 30;8(9):e76071. doi: 10.1371/journal.pone.0076071.

20.

Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM?

Gras L, Geskus RB, Jurriaans S, Bakker M, van Sighem A, Bezemer D, Fraser C, Prins JM, Berkhout B, de Wolf F; ATHENA National Observational Cohort..

PLoS One. 2013 May 27;8(5):e64437. doi: 10.1371/journal.pone.0064437.

Items per page

Supplemental Content

Loading ...
Support Center